Focused On-demand Library for E3 ubiquitin-protein ligase TRIM37

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

Mulibrey nanism protein; RING-type E3 ubiquitin transferase TRIM37; Tripartite motif-containing protein 37

Alternative UPACC:

O94972; A8K0V9; A8K8U4; A8MZ79; B4DGZ3; F8WEE6; Q7Z3E6; Q8IYF7; Q8WYF7


E3 ubiquitin-protein ligase TRIM37, also known as Mulibrey nanism protein, plays a crucial role in cellular processes including preventing centriole reduplication, mediating transcriptional repression through histone H2A monoubiquitination, and enhancing peroxisome import by stabilizing PEX5. Its anti-HIV activity further underscores its biological significance.

Therapeutic significance:

Linked to Mulibrey nanism, a growth disorder with severe clinical manifestations, TRIM37's genetic variants underscore its therapeutic potential. Understanding TRIM37's role could open doors to innovative treatments for Mulibrey nanism and related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.